Mraz Amerine & Associates’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$266K Hold
4,550
– – 0.04% 146
2026
Q2
$255K Hold
4,550
– – 0.04% 156
2026
Q1
$218K Buy
+4,550
New +$199K 0.03% 165

Other funds holding RPRX

Mraz Amerine & Associates's RPRX Position: Q3 2026 in Review

Mraz Amerine & Associates held its Royalty Pharma (RPRX) position steady in Q3 2026 at 4,550 shares worth $266K. The position accounts for 0.04% of the portfolio, ranked #146.

Mraz Amerine & Associates first reported a position in RPRX in Q1 2026 and has held it in 3 quarters since. 707 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Mraz Amerine & Associates held 4,550 shares of Royalty Pharma worth $266K as of Q3 2026.
  • Mraz Amerine & Associates left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up 0.04% of Mraz Amerine & Associates's portfolio in Q3 2026, its #146 holding.
  • Mraz Amerine & Associates first reported a position in Royalty Pharma in Q1 2026 and has held it in 3 quarters since.
  • 707 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Mraz Amerine & Associates's 13F filing for Q3 2026, filed 30 Oct 2026.